Tom Lawrie-Fussey and Lucy Sheldon introduce “Wizard of Oz” testing, named after the classic novel and film, whereby experimenters can field test concepts at a very early stage by giving the illusion of a finished product, saving potential costly and time-consuming changes further along the development process.
John Pritchard discusses the history of the nebuliser, its fall in popularity with the advent of DPIs and pMDIs, and its current resurgence due to the success of the mesh nebuliser, continuing on to how changing the development paradigm to utilise nebuliser technology more effectively can have significant benefits.
Whilst there is much discussion on how to apply connectivity and smart devices to therapies, there is far less dialogue concerning the challenges inherent to the digital architecture needed to make such innovations work in practice. Andreas Schneider introduces YDS SmartServices™, Ypsomed’s digital turnkey solution to effectively embed smart devices in a broader digital ecosystem.
David Belton highlights an often undiscussed aspect of the move towards connected drug delivery devices, the impact on manufacturing. Using inhalers as a reference point, he runs through several of the concerns and decisions that will need to be addressed for successful mass production of such devices.
Onejet is the first motor-driven, disposable and connected autoinjector. It's compatible with standard primary containers and is customisable allowing it to easily deliver high viscosity products. Injection data (time, doses and date) are transferred to a mobile app via Bluetooth, allowing monitoring of key treatment information.
With an eye on the current trends and range of innovations in the sector, particularly data and connectivity technology, Uri Baruch, Head of Drug Delivery, Cambridge Design Partnership, looks back on how far injectable drug delivery has come in the past thirty years, and forward to what the future may hold.